Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
A phase 1/2 trial of Fruquintinib in non-small-cell lung cancer and small-cell lung cancer, run by Immunitas Therapeutics, active and no longer recruiting.
Overview
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas is a phase 1/2 interventional study registered as NCT05565417 by Immunitas Therapeutics, with 67 participants enrolled, started 2022-11-28 and due to reach its primary completion in 2026-01. Interventions recorded: IMT-009, Fruquintinib. Conditions listed: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of IDP-001 in Advanced or Metastatic Solid Tumors
Shares Cutaneous squamous cell carcinoma, Head and neck squamous cell carcinoma, Non-small-cell lung cancer.
- TrialA Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Shares Cutaneous squamous cell carcinoma, Head and neck squamous cell carcinoma, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
Shares Fruquintinib, Colorectal cancer.
- TrialA Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
Shares Fruquintinib, Colorectal cancer.
- TreatmentHMBD-001
Shares Cutaneous squamous cell carcinoma, Head and neck squamous cell carcinoma, Non-small-cell lung cancer.
- TrialFRESCO-2
Shares Fruquintinib, Colorectal cancer.
- TrialInjection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu,
Shares Fruquintinib, Colorectal cancer.
- TrialAn Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
Shares Cutaneous squamous cell carcinoma, Head and neck squamous cell carcinoma.